File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

TitleEfficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Authors
Cheng, ALCornelio, GShen, LPrice, TYang, TSChung, IJDai, GHLin, JKSharma, AYeh, KHMa, BZaatar, AGuan, ZMasood, NSrimuninnimit, VYau, TCCGibbs, PWang, XDoval, DCSeung-Taek, OShim, BYGorospe, CWang, HMSirachainan, EHill, ASuh, KWBeier, FChatterjee, SLim, R
KeywordsDepth of response
Dosing schedule
Early tumor shrinkage
Erbitux
mCRC
Issue Date2017
PublisherCancer Information Group, LP. The Journal's web site is located at http://www.clinical-colorectal-cancer.com
Citation
Clinical Colorectal Cancer, 2017, v. 16 n. 2, p. e73-e88 How to Cite?
DOI: http://dx.doi.org/10.1016/j.clcc.2016.08.005
Persistent Identifierhttp://hdl.handle.net/10722/236419
ISSN
1533-0028
2021 Impact Factor: 4.035
2020 SCImago Journal Rankings: 1.402
ISI Accession Number ID
WOS:000404443500010

 

DC FieldValueLanguage
dc.contributor.authorCheng, AL-
dc.contributor.authorCornelio, G-
dc.contributor.authorShen, L-
dc.contributor.authorPrice, T-
dc.contributor.authorYang, TS-
dc.contributor.authorChung, IJ-
dc.contributor.authorDai, GH-
dc.contributor.authorLin, JK-
dc.contributor.authorSharma, A-
dc.contributor.authorYeh, KH-
dc.contributor.authorMa, B-
dc.contributor.authorZaatar, A-
dc.contributor.authorGuan, Z-
dc.contributor.authorMasood, N-
dc.contributor.authorSrimuninnimit, V-
dc.contributor.authorYau, TCC-
dc.contributor.authorGibbs, P-
dc.contributor.authorWang, X-
dc.contributor.authorDoval, DC-
dc.contributor.authorSeung-Taek, O-
dc.contributor.authorShim, BY-
dc.contributor.authorGorospe, C-
dc.contributor.authorWang, HM-
dc.contributor.authorSirachainan, E-
dc.contributor.authorHill, A-
dc.contributor.authorSuh, KW-
dc.contributor.authorBeier, F-
dc.contributor.authorChatterjee, S-
dc.contributor.authorLim, R-
dc.date.accessioned2016-11-25T00:53:08Z-
dc.date.available2016-11-25T00:53:08Z-
dc.date.issued2017-
dc.identifier.citationClinical Colorectal Cancer, 2017, v. 16 n. 2, p. e73-e88-
dc.identifier.issn1533-0028-
dc.identifier.urihttp://hdl.handle.net/10722/236419-
dc.languageeng-
dc.publisherCancer Information Group, LP. The Journal's web site is located at http://www.clinical-colorectal-cancer.com-
dc.relation.ispartofClinical Colorectal Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectDepth of response-
dc.subjectDosing schedule-
dc.subjectEarly tumor shrinkage-
dc.subjectErbitux-
dc.subjectmCRC-
dc.titleEfficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.clcc.2016.08.005-
dc.identifier.scopuseid_2-s2.0-85001720473-
dc.identifier.hkuros270526-
dc.identifier.volume16-
dc.identifier.issue2-
dc.identifier.spagee73-
dc.identifier.epagee88-
dc.identifier.isiWOS:000404443500010-
dc.publisher.placeUnited States-
dc.identifier.issnl1533-0028-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats